These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. First biosimilar drug approved for sale in the United States. Hede K J Natl Cancer Inst; 2015 Jul; 107(7):. PubMed ID: 26142444 [No Abstract] [Full Text] [Related]
4. Biosimilars battle rages on, Amgen fights both sides. Senior M Nat Biotechnol; 2013 Apr; 31(4):269-70. PubMed ID: 23563402 [No Abstract] [Full Text] [Related]
5. Biosimilars Ready, At Last, To Make Their Entrance: Stars Are Born or Do They Fizzle? Reinke T Manag Care; 2017 Mar; 26(3):20-23. PubMed ID: 28510515 [TBL] [Abstract][Full Text] [Related]
6. The Biosimilar Pipeline Seams Seem To Be Bursting. Reinke T Manag Care; 2017 Mar; 26(3):24-25. PubMed ID: 28510516 [TBL] [Abstract][Full Text] [Related]
7. Biosimilars for Rheumatoid Arthritis: Don't Count Them Out Quite Yet. Rychlick N Manag Care; 2018 Jan; 27(1):29. PubMed ID: 29369768 [TBL] [Abstract][Full Text] [Related]
8. Competition in the Age of Biosimilars. Chandra A; Vanderpuye-Orgle J JAMA; 2015 Jul; 314(3):225-6. PubMed ID: 26197179 [No Abstract] [Full Text] [Related]
10. Europe offers example for approving biosimilars. Carroll J Manag Care; 2013 Sep; 22(9):4-5. PubMed ID: 24167835 [No Abstract] [Full Text] [Related]
11. The comparability conundrum: biosimilars in the United States, Europe and Canada. Courage N; Parsons A Food Drug Law J; 2011; 66(2):203-24, i-ii. PubMed ID: 24505840 [TBL] [Abstract][Full Text] [Related]
12. The constitutional protection of trade secrets and patents under the Biologics Price Competition and Innovation Act of 2009. Epstein RA Food Drug Law J; 2011; 66(3):285-328. PubMed ID: 24505851 [TBL] [Abstract][Full Text] [Related]
13. Bullying biosimilars: cheaper drugs stymied in USA. The Lancet Gastroenterology Hepatology Lancet Gastroenterol Hepatol; 2018 Jun; 3(6):371. PubMed ID: 29739669 [No Abstract] [Full Text] [Related]
14. Obstacles to the Adoption of Biosimilars for Chronic Diseases. Hakim A; Ross JS JAMA; 2017 Jun; 317(21):2163-2164. PubMed ID: 28459924 [No Abstract] [Full Text] [Related]
15. Biosimilars: where we were and where we are. Challand R; Gorham H; Constant J J Biopharm Stat; 2014; 24(6):1154-64. PubMed ID: 25036475 [TBL] [Abstract][Full Text] [Related]
16. Biosimilars: the need, the challenge, the future: the FDA perspective. Epstein MS; Ehrenpreis ED; Kulkarni PM; Am J Gastroenterol; 2014 Dec; 109(12):1856-9. PubMed ID: 24957160 [TBL] [Abstract][Full Text] [Related]
17. FDA Biosimilar Action Plan: could improving pharmacovigilance of biologics improve patient and physician confidence in biosimilars? Jordan JB; Christl L Expert Opin Drug Saf; 2020 Mar; 19(3):229-232. PubMed ID: 32098520 [No Abstract] [Full Text] [Related]
18. Forum discusses biosimilars, better biologicals. Thompson CA Am J Health Syst Pharm; 2011 Dec; 68(23):2210. PubMed ID: 22095804 [No Abstract] [Full Text] [Related]
19. Regulatory and cost barriers are likely to limit biosimilar development and expected savings in the near future. Grabowski HG; Guha R; Salgado M Health Aff (Millwood); 2014 Jun; 33(6):1048-57. PubMed ID: 24889955 [TBL] [Abstract][Full Text] [Related]
20. Considerations in the early development of biosimilar products. Li EC; Abbas R; Jacobs IA; Yin D Drug Discov Today; 2015 May; 20 Suppl 2():1-9. PubMed ID: 25572407 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]